Enprostil, a prostaglandin E2 analogue, in the treatment of duodenal ulcer; a multicentre ' comparison with cimetidine
Enprostil, a prostaglandin E2 analogue, in the treatment of duodenal ulcer; a multicentre ' comparison with cimetidine
复制标题
Enprostil，一种前列腺素E2类似物，用于治疗十二指肠溃疡；
DOI：
10.1111/j.1365-2036.1988.tb00708.x
复制
发表时间：
1988
影响因子：
7.6
通讯作者：
E. Barker
中科院分区：
文献类型：
--
作者：
R. Jazrawi;T. Northfield;P. I. Reed;R. Cockel;K. Schiller;E. Barker
在一项多中心试验中，120 名经内镜诊断的十二指肠溃疡患者被随机分配接受 35 μg enprostil b.d. 或 35 μg enprostil b.d. 治疗。或 400 mg 西咪替丁 b.d.在双盲的基础上进行长达 6 周的研究。 6周后，82%（42/51）的恩前列素治疗患者和92%（44/48）的西咪替丁治疗患者痊愈。相应的意向治疗治愈率分别为 70% 和 76%。在任何时间，治疗之间在治愈率或症状控制方面均未检测到显着差异。 14 名服用恩前列素的患者和 17 名服用西咪替丁的患者报告了副作用；没有一例严重，但分别导致一名和两名患者退出。发现恩前列素的功效和耐受性与西咪替丁相似。
In a multicentre trial, 120 patients with endoscopically diagnosed duodenal ulcer were randomly allocated to treatment with either 35 μg enprostil b.d. or 400 mg cimetidine b.d. for up to 6 weeks on a double‐blind basis. After 6 weeks, 82% (42/51) of enprostil‐treated patients and 92% (44/48) of cimetidine‐treated patients were healed. Corresponding healing figures on an intention‐to‐treat basis were 70% and 76%. No significant differences were detected between treatments with respect to healing rates or symptom control at any time. Side‐effects were reported by 14 patients taking enprostil and 17 patients taking cimetidine; none were serious but they resulted in withdrawal of one and two patients respectively. Enprostil was found to be similar in efficacy and tolerance to cimetidine.